Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 98420X202 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
FMR LLC
13G/A
Amendment 2
|
4.6% |
10/7/2026
Event 9/30/2026
|
|
| FMR LLC | 4.6% | ||
| Abigail P. Johnson | 4.6% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G
|
5.6% |
9/21/2026
Event 9/14/2026
|
|
| Venrock Healthcare Capital Partners III, L.P. | 5.6% | ||
| VHCP Co-Investment Holdings III, LLC | 5.6% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 5.6% | ||
| VHCP Management III, LLC | 5.6% | ||
| VHCP Management EG, LLC | 5.6% | ||
| Nimish Shah | 5.6% | ||
| Bong Y. Koh | 5.6% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 2
|
8.1% |
8/14/2026
Event 6/30/2026
|
|
| Perceptive Advisors LLC | 8.1% | ||
| Joseph Edelman | 8.1% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 8.1% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
8.3% |
8/14/2026
Event 6/30/2026
|
|
| Deep Track Capital, LP | 8.3% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 7.2% | ||
| David Kroin | 8.3% | ||
| Deep Track Special Opportunities Fund, LP. | 1.2% | ||
| BlackRock, Inc. 13G | 5.9% |
7/30/2026
Event 6/30/2026
|
|
|
Perceptive Advisors LLC
13G/A
Amendment 1
|
7.3% |
5/15/2026
Event 3/31/2026
|
|
| Perceptive Advisors LLC | 7.3% | ||
| Joseph Edelman | 7.3% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 7.3% | ||
|
Morgan Stanley
13G/A
Amendment 1
|
10.2% |
3/6/2026
Event 2/28/2026
|
|
| Morgan Stanley | 10.2% | ||
| Morgan Stanley Investment Management Inc. | 10.2% | ||
| Inception Trust | 5.2% | ||
|
Trails Edge Capital Partners, LP
13G/A
Amendment 1
|
5.8% |
2/17/2026
Event 12/31/2025
|
|
| Trails Edge Capital Partners, LP | 5.8% | ||
| Trails Edge Biotechnology Master Fund, LP | 5.8% | ||
| Ortav Yehudai | 5.8% | ||
|
Bain Capital Life Sciences Fund, L.P.
13G/A
Amendment 1
|
7.4% |
2/17/2026
Event 12/31/2025
|
|
| Bain Capital Life Sciences Fund, L.P. | 0% | ||
| Bain Capital Life Sciences Fund II, L.P. | 0.1% | ||
| BCIP Life Sciences Associates, LP | <0.1% | ||
| BCLS II Investco, LP | 0.8% | ||
| BCLS I Investco, LP | 0.1% | ||
| BCLS II Equity Opportunities, LP | 7.4% | ||
|
Saturn V Capital Management LP
13G
|
7.4% |
2/17/2026
Event 10/24/2025
|
|
| Saturn V Capital Management LP | 7.4% | ||
| Xiaoying Tian | 7.4% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
3.9% |
2/17/2026
Event 12/31/2025
|
|
| Biotechnology Value Fund L P | 2.1% | ||
| BVF I GP LLC | 2.1% | ||
| Biotechnology Value Fund II LP | 1.5% | ||
| BVF II GP LLC | 1.5% | ||
| Biotechnology Value Trading Fund OS LP | 0.2% | ||
| BVF Partners OS Ltd. | 0.2% | ||
| BVF GP Holdings LLC | 3.6% | ||
| BVF Partners L P/IL | 3.9% | ||
| BVF Inc/IL | 3.9% | ||
| Lampert Mark N | 3.9% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
2.8% |
2/13/2026
Event 12/31/2025
|
|
| Nantahala Capital Management, LLC | 2.8% | ||
| Wilmot B. Harkey | 2.8% | ||
| Daniel Mack | 2.8% | ||
|
Morgan Stanley
13G
|
9.4% |
2/12/2026
Event 12/31/2025
|
|
| Morgan Stanley | 9.4% | ||
| Morgan Stanley Investment Management Inc. | 9.4% | ||
|
FMR LLC
13G/A
Amendment 1
|
9.7% |
2/5/2026
Event 10/31/2025
|
|
| FMR LLC | 9.7% | ||
| Abigail P. Johnson | 9.7% | ||
|
Empery Asset Management, LP
13G/A
Amendment 1
|
10.0% |
1/15/2026
Event 12/31/2025
|
|
| Empery Asset Management, LP | 10.0% | ||
| Ryan M. Lane | 10.0% | ||
|
Nantahala Capital Management, LLC
13G
|
10.0% |
11/14/2025
Event 9/30/2025
|
|
| Nantahala Capital Management, LLC | 10.0% | ||
| Wilmot B. Harkey | 10.0% | ||
| Daniel Mack | 10.0% | ||
|
FMR LLC
13G
|
14.8% |
11/7/2025
Event 10/31/2025
|
|
| FMR LLC | 14.8% | ||
| Abigail P. Johnson | 14.8% | ||
|
Perceptive Advisors LLC
13G
|
7.6% |
11/3/2025
Event 10/27/2025
|
|
| Perceptive Advisors LLC | 7.6% | ||
| Joseph Edelman | 7.6% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 7.6% | ||
|
Growth Equity Opportunities 18 VGE, LLC
13D/A
Amendment 4
|
6.2% |
10/29/2025
Event 10/27/2025
|
|
| Growth Equity Opportunities 18 VGE, LLC | 6.2% | ||
| NEA 18 Venture Growth Equity, L.P. | 6.2% | ||
| NEA Partners 18 VGE, L.P. | 6.2% | ||
| Nea 18 Vge GP, LLC | 6.2% | ||
| Ali Behbahani | 6.2% | ||
| Carmen Chang | 6.2% | ||
| Anthony A. Florence, Jr. | 6.2% | ||
| Mohamad H. Makhzoumi | 6.2% | ||
| Edward T. Mathers | 6.2% | ||
| Scott D. Sandell | 6.2% | ||
| Paul Walker | 6.2% | ||
| Rick Yang | 6.2% | ||
|
Empery Asset Management, LP
13G
|
10.0% |
10/21/2025
Event 9/30/2025
|
|
| Empery Asset Management, LP | 10.0% | ||
| Lane Ryan M. | 10.0% | ||
| Hoe Martin D. | 10.0% | ||
|
Coastlands Capital LP
13G
|
10.0% |
10/3/2025
Event 10/3/2025
|
|
| Coastlands Capital LP | 10.0% | ||
| Coastlands Capital Partners LP | 10.0% | ||
| Coastlands Capital GP LLC | 10.0% | ||
| Coastlands Capital LLC | 10.0% | ||
| Matthew D. Perry | 10.0% | ||
|
Bain Capital Life Sciences Fund, L.P.
13G
|
10.0% |
9/15/2025
Event 9/9/2025
|
|
| Bain Capital Life Sciences Fund, L.P. | 10.0% | ||
| Bain Capital Life Sciences Fund II, L.P. | 10.0% | ||
| BCIP Life Sciences Associates, LP | 10.0% | ||
| BCLS II Investco, LP | 10.0% | ||
| BCLS I Investco, LP | 10.0% | ||
| BCLS II Equity Opportunities, LP | 10.0% | ||
|
Biotechnology Value Fund L P
13G
|
9.9% |
8/20/2025
Event 8/13/2025
|
|
| Biotechnology Value Fund L P | 5.2% | ||
| BVF I GP LLC | 5.2% | ||
| Biotechnology Value Fund II LP | 4.0% | ||
| BVF II GP LLC | 4.0% | ||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||
| BVF Partners OS Ltd. | 0.6% | ||
| BVF GP Holdings LLC | 9.2% | ||
| BVF Partners L P/IL | 9.9% | ||
| BVF Inc/IL | 9.9% | ||
| Lampert Mark N | 9.9% | ||
|
Deep Track Capital, LP
13G
|
10.0% |
8/19/2025
Event 8/12/2025
|
|
| Deep Track Capital, LP | 10.0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 10.0% | ||
| David Kroin | 10.0% | ||
|
Trails Edge Capital Partners, LP
13G
|
9.9% |
8/18/2025
Event 8/11/2025
|
|
| Trails Edge Capital Partners, LP | 9.9% | ||
| Trails Edge Biotechnology Master Fund, LP | 9.9% | ||
| Ortav Yehudai | 9.9% | ||
|
Coastlands Capital LP
13D
|
10.0% |
8/18/2025
Event 8/11/2025
|
|
| Coastlands Capital LP | 10.0% | ||
| Coastlands Capital Partners LP | 10.0% | ||
| Coastlands Capital GP LLC | 10.0% | ||
| Coastlands Capital LLC | 10.0% | ||
| Matthew D. Perry | 10.0% | ||
|
Growth Equity Opportunities 18 VGE, LLC
13D/A
Amendment 3
|
10.0% |
8/15/2025
Event 8/13/2025
|
|
| Growth Equity Opportunities 18 VGE, LLC | 10.0% | ||
| NEA 18 Venture Growth Equity, L.P. | 10.0% | ||
| NEA Partners 18 VGE, L.P. | 10.0% | ||
| Nea 18 Vge GP, LLC | 10.0% | ||
| Ali Behbahani | 10.0% | ||
| Carmen Chang | 10.0% | ||
| Anthony A. Florence, Jr. | 10.0% | ||
| Mohamad H. Makhzoumi | 10.0% | ||
| Edward T. Mathers | 10.0% | ||
| Scott D. Sandell | 10.0% | ||
| Paul Walker | 10.0% | ||
| Rick Yang | 10.0% | ||
|
Bain Capital Life Sciences Fund, L.P.
13D
|
10.0% |
8/13/2025
Event 8/11/2025
|
|
| Bain Capital Life Sciences Fund, L.P. | 10.0% | ||
| Bain Capital Life Sciences Fund II, L.P. | 10.0% | ||
| BCIP Life Sciences Associates, LP | 10.0% | ||
| BCLS II Investco, LP | 10.0% | ||
| BCLS I Investco, LP | 10.0% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 3.0% |
7/18/2025
Event 6/30/2025
|